EUVIMEDEUVIMED entdecken
Kommentar

Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns

Naomi E Aronson, Kendall Billick

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad248 ↗

Kurz gefasst

Kommentar in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Naomi E Aronson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Leishmania braziliensis, Leishmaniasis, Cutaneous, Antiprotozoal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmania braziliensisLeishmaniasis, CutaneousAntiprotozoal AgentsHumansMeglumine AntimoniateBrazil

Substanzen

Meglumine AntimoniateAntiprotozoal Agents

Autor:innen und Institutionen

  • Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.

Zitieren

APA

Aronson, N. E., & Billick, K. (2023). Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad248

Vancouver

Aronson NE, Billick K. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad248

BibTeX
@article{Aronson2023,
  author = {Aronson, Naomi E and Billick, Kendall},
  title = {Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad248}
}
Kostenlos starten →